Hemostasis and Tissue Sealing Agents Market

Hemostasis and Tissue Sealing Agents Market Outlook (2022 to 2027)

The global hemostasis and tissue sealing agents market is expected to increase at a high CAGR of 8.5% and climb from a market valuation of US$ 5 billion in 2022 to US$ 7.6 billion by the end of 2027.

Global sales of topical hemostats are predicted to rise at an impressive CAGR of 9.5% owing to the rising prevalence of chronic blood disorders across the world.

Report Attributes	Details
Hemostasis and Tissue Sealing Agents Market Size (2022E)	US$ 5 Billion
Forecasted Market Value (2027F)	US$ 7.6 Billion
Global Market Growth Rate (2022 to 2027)	8.5% CAGR
China Market Growth Rate (2022 to 2027)	13% CAGR
Key Companies Profiled	Advance Medical Solution (AMS) Group Plc; B Braun Medical, Inc.; Baxter; Biomet, Inc.; C R Bard, Inc.; Cohera Medical, Inc.; Cohesion Technologies, Inc.; Covidien Plc.; CryoLife, Inc.; HyperBranch Medical Technology.; Integra Life Sciences Corporation; Johnson & Johnson; MIL Laboratories Pvt., Ltd.; Pfizer, Inc.; Smith & Nephew

Demand Analysis of Hemostasis and Tissue Sealing Agents (2017 to 2021) Vs. Market Forecasts (2022 to 2027)

Hemostats and sealants are medical equipment used to stop bleeding and haemorrhage brought on by wounds and surgical operations. They are extremely helpful aids to contemporary surgical techniques. However, severe blood loss that results from serious surgery or trauma cannot be prevented by the body's normal healing mechanisms.

Hemostats and tissue sealing agents help in such circumstances by reducing blood loss and promoting wound healing. The first stage of hemostasis wound healing can last for 2 days. Ice can aid with acute discomfort from haemarthrosis; other treatments can be used that won't affect hemostasis and coagulation.

Topical hemostats, such as active hemostats, mechanical hemostats, and flowable hemostats-solutions administered topically are directly applied to the bleeding site-along with natural and artificial tissue sealants serve as an addition to the body's normal hemostasis process and are used locally to control bleeding.

Topical hemostats are used primarily intraoperative and less frequently postoperatively. Also, bone bleeding, gushing venous type bleeds, raw surface bleeding, and needle-opening bleeding can all be treated with these products.

A typical hemostasis valve features a rotating seal at the end that can be opened or closed in response to the insertion or removal of a wire, microcatheter, or guidewire. This frequently causes considerable back bleeding.

Due to a rise in demand supported by increasing surgical volumes, the market is anticipated to have profitable growth over the next five years. Among the main factors influencing the market are the rise in the elderly population and the high frequency of chronic diseases.

During the forecast period of 2022 to 2027, the global market share of hemostasis and tissue sealing agents is expected to experience significant growth due to the increase in the use of hemostats product lines to prevent blood loss in a variety of general as well as less invasive surgical interventions and the preference for minimally-invasive procedures over other traditional procedures.

According to this market study of hemostasis and tissue sealing agents, by Fact.MR, a market research and competitive intelligence provider, the global market is expected to reach a valuation of US$ 7.6 billion by 2027.

What’s Augmenting Sales of Hemostasis and Tissue Sealing Agents?

“Market Gaining Prominence on Back of High Demand for Minimally-invasive Surgeries”

Demand for minimally-invasive procedures has significantly increased in recent years. Minimally-invasive operations include benefits such as shorter hospital stay, minimal incisions, fewer post-surgical problems, and quicker recovery time.

A majority of minimally-invasive procedures use systemic hemostatic agents such as gelatin- and collagen-based powder hemostatic agents. Complex procedures can be carried out easily due to these medications.

• Approximately 234.2 million major surgical surgeries are done annually by various hospitals and surgical centres around the world, according to a World Health Organization (WHO) study.

The need for hemostat and tissue sealing agents is therefore increased by the rising number of surgeries and the preference for minimally-invasive procedures.

“Increasing Incidence of Chronic Disorders Needing Surgery”

Patients who are elderly need immediate attention and are more likely to get wounds and injuries that take a long time to recover. The market is predicted to develop as a result of an increase in the number of common injuries and wounds due to a demographic trend toward an active lifestyle.

Most chronic conditions ultimately necessitate surgical procedures, which subsequently promote market growth. A few chronic illnesses that call for these goods are hernia fixation, diabetes, spinal injuries, urological disorders, ocular injuries and replacements, and burns.

These solutions were chosen over alternative wound closure techniques, which resulted in an expansion of their applications, particularly in endoscopic treatments. Endoscopic hemostatic therapy is effective for the treatment of peptic ulcers.

The market for hemostasis and tissue sealing products serves patients with everything from minor wounds to burns and neurosurgical treatment.

Hemostatic agents in surgery are particularly used in minimally-invasive urological procedures, which are supporting the market growth. Following general procedures, cardiovascular diseases see the biggest demand. Higher applicability in cardiovascular illnesses is attributable to sealants' and hemostats' superior clinical outcomes when compared to other wound closure methods.

What is Hampering Hemostasis and Tissue Sealing Agents Market Size Growth?

“High Production Cost & Strict Regulatory Requirements”

The development of hemostat and tissue sealant solutions is a time-consuming and expensive process. Regulatory approval of hemostat products requires reliable scientific proof, carefully monitored research, and case studies with documentation.

Although firms spend a lot of money developing hemostat products, there is a low success rate for getting these medications approved by regulatory bodies. The poor approval rate of hemostat solutions has been linked to the low efficacy and safety of the medications.

Due to difficulties hemostat manufacturers encountered in clinical research, only a few businesses have reached the market. The market for hemostasis and tissue sealing agents is hampered as a result.

How is the Start-up Ecosystem for Hemostasis and Tissue Sealing Agents Evolving?

“New Market Entrants Can Mimic Strategies of Key Players to Grow”

AVS Electrotherm, Ortholink Marketing, AGD Biomedicals, Globalstar Company, and Sysmex are a few of the start-up businesses that are vying for a share in the market.

To gauge the interest of potential customers and build a larger clientele, hemostasis and tissue sealing agent manufacturers are utilising a variety of marketing methods, including new product releases, geographic growth, partnerships, mergers and acquisitions, and collaborations.

• In terms of hemostasis instrumentation, Sysmex leads the world market. To create a mutually beneficial partnership that strengthens each party's advantages in the hemostasis market, Sysmex has maintained its distribution arrangement with Siemens, a world leader in hemostasis reagents.

New companies can follow the successful strategies of established companies to carve a space for themselves in this niche market.

Which Regions Account for High Demand for Hemostasis and Tissue Sealing Agents?

“North America & Asia Pacific Lead Global Market Handsomely”

The market for hemostasis and tissue sealing agents is dominated by the North America region due to the rising incidence of cancer, diabetes, and cardiovascular diseases.

Due to the rising frequency of various hemostasis illnesses, the involvement of regional and international industry players, and the significant investments made in R&D of hemostasis and tissue sealing agents, Europe also presents prospective growth possibilities in the hemostasis products market.

A significant growth rate in the Asia Pacific is anticipated between 2022 and 2027 as a result of an increase in surgical and medical tourism. Over the forecast period, an increase in traffic accidents in the Asia Pacific region that result in trauma admissions to emergency rooms also supports market expansion in the region.

• The Ministry of Road Transport and Highways, Government of India, reports that a total of 366,138 road accidents were reported during the year 2020, resulting in 131,714 fatalities and 348,279 injuries. Sadly, the age range most frequently impacted by traffic accidents is 18 to 45 years old, which accounts for around 70% of all accidental fatalities.

Latin America and the Middle East & Africa regions are expected to have relatively lower market shares and growth rates over the coming years.

Country-wise Analysis

What is Allowing the U.S. Hemostasis and Tissue Sealing Agents Market to Dominate North America?

“Increased Prevalence of Cardiovascular Illnesses & Blood Clotting Issues”

Due to growing healthcare infrastructure, widespread use of cutting-edge automated analyzers, and a sizable patient base, the U.S. currently holds a monopoly on the North America hemostasis and tissue sealing agents market.

• Sysmex Corporation introduced the Automated Blood Coagulation Analyzers CN-6000 and CN-3000 in 2018, which are next-generation analyzers in the hemostasis sector.

Furthermore, technological developments have made healthcare services more accessible, and the introduction of new manufacturers will probably drive market expansion in the nation in the coming years. Also, demand for hemostasis diagnostics is being aggressively driven up by the rising prevalence of several blood clot illnesses.

• The US Centers for Disease Control and Prevention (CDC) estimates that one in 5,617 live male births has hemophilia. In the US, there are 30,000 to 33,000 males who have hemophilia.
• According to the Centers for Disease Control and Prevention, one person in the United States passes away from cardiovascular disease every 34 seconds. In the United States, heart disease caused the deaths of almost 697,000 people in 2020, accounting for 1 in 5 deaths.

Will China Be a Lucrative Market for Hemostasis and Tissue Sealing Agents?

“Presence of Top Pharmaceutical & Biotechnology Businesses”

The most lucrative market is thought to be China, which is predicted to account for a higher market value. Due to its technologically advanced healthcare system, innovative therapies, and substantial patient population, China is predicted to lead the Asia Pacific hemostasis and tissue sealing agents market in terms of revenue share and grow at a significantly faster rate than other countries.

The presence of leading pharmaceutical and biotech firms engaged in the development of therapies is credited with the expansion of the hemostasis and tissue sealing agents market in China. Furthermore, the market is supported by a sound healthcare system. Also, there are chances for market expansion due to expanding cardiovascular disorder prevalence in the nation and rising hemostasis product demand.

The China hemostasis and tissue sealing agents market is expected to rise at a high CAGR of 13% from 2022 to 2027 and reach US$ 1.6 billion by 2027.

Category-wise Analysis

Why are Topical Hemostats Widely Popular?

“Cost-effective, Simple to Apply, & Effective End Results Make Topical Hemostats Popular Choice”

Topical hemostasis solutions are in demand because they are affordable, effective, simple to apply, and biodegradable. In surgical operations, topical hemostasis agents are most frequently used. Thus, the segmental expansion will be favoured by the rising number of surgical procedures.

The segment of infusible hemostats is expected to account for a sizeable market share during the projected period. When it comes to managing bleeding in patients with blood clotting disorders such as haemophilia, Von Willebrand disease (vWD), and dysfibrinogenemia, infusible hemostats are among the most popular and commonly used hemostatic medicines.

Global demand for topical hemostatic agents is predicted to rise at an impressive CAGR of 9.5% from 2022 to 2027 and reach a valuation of US$ 5.5 billion by 2027.

Competitive Landscape

The leading companies in the global hemostasis and tissue sealing agents market are involved in product launches, manufacturing technologically cutting-edge solutions, acquisitions, and joint ventures with other businesses.

These tactics are probably going to help the market for tissue sealing and hemostasis agents increase around the globe.

• The Terumo Corporation introduced AQUABRID, a novel surgical sealant product, to the EMEA market on January 26, 2020. Using this product during aortic surgery helps to halt bleeding.
• Johnson & Johnson (Ethicon, Inc.) (U.S) dominates the market for tissue sealants and tissue glue. The company enjoys a strong regional presence and a well-known brand. It also offers a wide variety of surgical sealants and adhesives, including some of the most recognizable brands.

Segmentation of Hemostasis and Tissue Sealing Agents Industry Research

• By Product :

  • Topical Hemostats
  • Adhesive & Tissue Sealants

• By End User :

  • Hospitals
  • Ambulatory Surgery Centers
  • Home Care Settings
  • Others

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • MEA